Microsatellite Instability and Loss of Heterozygosity in CCND1 Microsatellite loci at Chr.11q13 in OSCC Patients with Therapeutic Validation
Article Sidebar
Main Article Content
Abstract
Background: Numerous prognostic biological markers linked to survival have been identified over the years; however, only few have undergone rigorous evaluation for their diagnostic accuracy. Molecular laboratory techniques like microarrays, microsatellites, and single-nucleotide polymorphisms (SNPs) have created new opportunities for diagnosing diseases, identifying chromosomal aberrations, and detecting point mutations for medical verification. The deviation of CCND1-cyclinD1 loci on chromosome 11Q13 is identified as a genetic marker for esophageal, breast, colon, rectal, and ovarian cancers.
Material and Methods: A total of 18 microsatellite markers located on 11q13 were analyzed in 150 patients with oral squamous cell carcinoma (OSCC), who were treated with cisplatin and capecitabine. The study aimed at early detection, clinical validation, and the establishment of genetic markers. We collected 150 primary tumor tissues and corresponding blood samples from patients visiting King George’s Medical University in Lucknow between 2010 and 2016. Tissue samples were obtained either at the time of investigational biopsy or during the surgical resection of the lesions.
Results: The overall incidence of loss of heterozygosity (LOH)/microsatellite instability (MSI) was 60%±20.84, with the frequency of LOH and MSI of individual markers ranging from 9% to 95%. LOH/MSI was relatively more frequently detected at five loci, namely, FGF4 (65.33%/11%), FGF3 (77.33%/13.23%), INT2 (64%/12.8%), CCND1 (88%/ 15.13%), and D11S2179 (61.33%/12.66%).
Conclusion: This report presents the initial findings suggesting a potential association between allelic loss at the CCND1 locus on chromosome 11q13 and the recurrence of OSCC in Indian patients treated with cisplatin and capecitabine. Further research in this area may provide valuable insights.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- ShareAlike — If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
References
.